www.sledai-2k.pdf

SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) quantifies current inflammatory disease activity over a defined recent window (commonly the prior 10 days). It assigns weighted points to specific clinical and laboratory features (e.g., seizures/psychosis, arthritis, rash, nephritis findings such as proteinuria/hematuria, low complement, anti–dsDNA).

The total score reflects how “active” lupus is right now and is often used in clinical trials and practice to track response to treatment. It is good for capturing change over time, but it may miss gradations of severity within a manifestation and can underrepresent some chronic/ongoing problems.

SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) is a standardized scoring system used to quantify how active lupus is right now (i.e., inflammatory activity), rather than long-term damage. It’s widely used in both clinical care and clinical trials to track change over time and to compare patients in a consistent way.

How it works

• It scores a fixed list of clinical and laboratory features of active SLE occurring within a recent time window (classically the prior 10 days).
• Each feature has a pre-assigned weight (more dangerous manifestations score higher).
• The total score is the sum of present items.

What it captures (examples)

• Neuropsychiatric activity (e.g., seizure, psychosis)
• Renal activity (e.g., active urinary sediment, proteinuria depending on version)
• Serositis (pleuritis/pericarditis), arthritis
• Mucocutaneous disease (rash, alopecia, oral ulcers)
• Labs reflecting immunologic activity: low complement, anti–dsDNA, plus cytopenias in some versions

Interpretation

• Higher score = more active disease; change in score is often more clinically useful than a single number.
• Common caveats: it can miss severity gradations within a domain and may undercount persistent, smoldering activity.

Interpreting a SLEDAI score (typical categories)

A commonly used clinical/trial categorization is:

• 0 = no activity
• 1–5 = mild activity
• 6–10 = moderate activity
• 11–19 = high activity
• ≥20 = very high activity

Many trials define “active” SLE as around ≥4 or ≥6, depending on the population and inclusion criteria (e.g., requiring room to improve).

Also, in drug trials, a key concept is meaningful improvement: the classic endpoint SRI-4 requires a ≥4-point decrease in (SELENA-)SLEDAI without specified worsening elsewhere.

Differences between SLEDAI variants you’ll encounter

1) Original SLEDAI

• 24 weighted items; scored as present/absent within a short lookback window (classically 10 days).

2) SLEDAI-2K

• Same 24 items and weighting, but it allows scoring of persistent active disease for certain manifestations (classically highlighted for proteinuria, and also allows ongoing activity in some mucocutaneous items rather than “new/relapse only” in the original).

3) SELENA-SLEDAI

• A modified SLEDAI used heavily in trials (notably biologic trials). Still 24 items, 0–105 total, and typically 10-day window.